Results 31 to 40 of about 19,471 (205)

Aplicação de estratégias no estado sólido visando ao aumento da solubilidade dos farmacos: cloridrato de terbinafina, carvedilol e nevirapina [PDF]

, 2014
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2014Em medicamentos administrados via oral, as características físico-químicas dos fármacos estão diretamente ...
Kuminek, Gislaine
core  

Systematic development of pH-independent controlled release tablets of carvedilol using central composite design and artificial neural networks

, 2013
The purpose of this study was to apply the optimization method incorporating artificial neural network (ANN) using pH-independent release of weakly basic drug, carvedilol from HPMC-based matrix formulation.
ÖNER, LEVENT, Kockan, Umit, EROĞLU, HAKAN, Aktas, Elcin   +3 more
core   +1 more source

The improvement chest x-ray after carvedilol therapy in heart failure due to left to right shunt, congenital heart disease [PDF]

, 2017
Background: Heart failure due to left to right shunt congenital heart defect will increase pulmonary blood flow and cause volume overload. This condition activated the sympathetic nervous system and the renin-angiotensin-aldosteron system.
Taufiq Hidayat, -, Teddy Ontoseno, -, Enny Zuraida, -, I Ketut Alit Utamayasa, -, Mahrus A. Rahman, -   +4 more
core   +1 more source

Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol

ESC Heart Failure
Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta‐blockers. Degenerative
Wei‐Chieh Lee, Yu‐Wen Lin, Jhih‐Yuan Shih, Zhih‐Cherng Chen, Nan‐Chun Wu, Wei‐Ting Chang   +5 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Efeito do carvedilol e monitoramento de terapias antioxidantes ao longo de 7 anos em pacientes cardiopatas chagásicos crônicos [PDF]

, 2011
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em FarmáciaIntrodução: A cardiopatia chagásica crônica (CCC) é considerada a causa mais comum de insuficiência cardíaca congestiva (ICC) com
Budni, Patrícia
core  

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Carvedilol Confers Ferroptosis Resistance in HL-1 Cells by Upregulating GPX4, FTH1, and FTL1 and Inducing Metabolic Remodeling Under Hypoxia/Reoxygenation

Antioxidants
Hypoxia/reoxygenation (HR) often occurs under cardiac pathological conditions, and HR-induced oxidative stress usually leads to cardiomyocyte damage. Carvedilol, a non-selective β-blocker, is used clinically to treat cardiac ischemia diseases.
Yi-Chin Li, Mei-Ling Cheng
doaj   +1 more source

HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA

Рациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate an influence of carvedilol on risk of hypoglycemia in patients with diabetes type 2 (D2) and chronic heart failure (CHF) treated with angiotensin converting enzyme (ACE) inhibitors.Material and methods. 13 patients (10 men, 3 women; aged
A. A. Aleksandrov, O. А. Shatskaya, S. S. Kuharenko, E. N. Drozdova, I. Z. Bondarenko, N. D. Tabidze, M. V. Shestakova   +6 more
doaj   +1 more source

Evaluation of Carvedilol in Prevention of First Attack of Variceal Hemorrhage in Patients with Liver Cirrhosis [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2012
Background and study aim: Carvedilol has beneficial effects on splanchnic haemodynamics following acute and chronic administration in cirrhosis. The aim of this study is to evaluate the role of carvedilol in prevention of first variceal bleeding in ...
Hosam Dawod, Eman Abdel Aal, Samy Essa, Ahmad Mahmod   +3 more
doaj   +1 more source